NEWS
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
Allarity Therapeutics announced that multiple patients in its Phase 2 trial of stenoparib for advanced ovarian cancer have exceeded 30 weeks of treatment. Stenoparib demonstrated significant tumor shrinkage and long-term disease stability, prompting the company to halt patient enrollment to focus on a follow-on trial aimed at regulatory approval. Dr. Kathleen N. Moore, the trial's Principal Investigator, highlighted the drug’s promising results and favorable tolerability compared to first-generation PARP inhibitors. CEO Thomas Jensen emphasized the drug's safety profile and its potential as a next-generation treatment. The trial, conducted in the US and UK, involved pre-screened patients using Allarity’s DRP® companion diagnostic system and a revised dosing regimen to optimize drug exposure. The PARP inhibitor market is evolving rapidly, with stenoparib positioned as a differentiated therapeutic product.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7384Visitors
Follow
SpecklesS : When will the party start?
Jaguar8 OP SpecklesS : We shall see. I haven’t entered yet.